Literature DB >> 24509826

Effect of different tacrolimus levels on early outcomes after kidney transplantation.

Shehzad Rehman1, Xuerong Wen1, Michael J Casey1, Alfonso H Santos1, Kenneth Andreoni2.   

Abstract

BACKGROUND: There is a paucity of modern data on the impact of high tacrolimus levels early after kidney transplantation. MATERIAL/
METHODS: This study analyzed the impact of various trough levels of tacrolimus in the first 2 weeks post-transplant on rates of delayed graft function (DGF), length of stay (LoS), hyperkalemia, hyperglycemia, and biopsy-proven acute rejection (BPAR) rates in the first 3 months post-transplant in a retrospective single-center cohort of patients. Patients were divided into 4 groups based on the average of two highest 12-hour trough tacrolimus levels: <10 ng/mL, 10-12 ng/mL, 12-15 ng/mL, >15 ng/mL.
RESULTS: The incidence of DGF was noted to be significantly higher in the <10 ng/mL, >15 ng/mL and the 12-15 ng/mL tacrolimus groups as compared to the 10-12 ng/mL group (49%, 25% and 4%, respectively, p≤0.0001). Mean LoS was also noted to be significantly higher in the >15 ng/mL tacrolimus group as compared to the 10-12 ng/mL group (7.4 days and 6.1 days respectively, p=0.0007). There was no difference in the rates of hyperkalemia, hyperglycemia or BPAR.
CONCLUSIONS: This is a modern confirmation of the association between higher tacrolimus levels early after kidney transplantation and increased rate of DGF and increased LoS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24509826     DOI: 10.12659/AOT.889858

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  7 in total

1.  Pre-Transplant Plasma Potassium as a Potential Risk Factor for the Need of Early Hyperkalaemia Treatment after Kidney Transplantation: A Cohort Study.

Authors:  Bram C S de Vries; Stefan P Berger; Stephan J L Bakker; Martin H de Borst; Margriet F C de Jong
Journal:  Nephron       Date:  2020-11-19       Impact factor: 2.847

2.  Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?

Authors:  Kinga Krzyżowska; Aureliusz Kolonko; Piotr Giza; Jerzy Chudek; Andrzej Więcek
Journal:  Biomed Res Int       Date:  2018-01-30       Impact factor: 3.411

3.  Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients.

Authors:  Hee-Yeon Jung; Min Young Seo; Yena Jeon; Kyu Ha Huh; Jae Berm Park; Cheol Woong Jung; Sik Lee; Seung-Yeup Han; Han Ro; Jaeseok Yang; Curie Ahn; Ji-Young Choi; Jang-Hee Cho; Sun-Hee Park; Yong-Lim Kim; Chan-Duck Kim
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

4.  Comparison of Transplant Outcomes for Low-level and Standard-level Tacrolimus at Different Time Points after Kidney Transplantation.

Authors:  Hee-Yeon Jung; Sun-Young Cho; Ji-Young Choi; Jang-Hee Cho; Sun-Hee Park; Yong-Lim Kim; Hyung-Kee Kim; Seung Huh; Dong Il Won; Chan-Duck Kim
Journal:  J Korean Med Sci       Date:  2019-03-22       Impact factor: 2.153

5.  Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.

Authors:  Michele Pinon; Amedeo De Nicolò; Antonio Pizzol; Miriam Antonucci; Antonio D'Avolio; Loredana Serpe; Dominic Dell'Olio; Silvia Catalano; Francesco Tandoi; Renato Romagnoli; Roberto Canaparo; Pier Luigi Calvo
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

6.  Prevalence and factors associated with hyperkalaemia in stable kidney transplant recipients.

Authors:  Maria Smyrli; Pantelis A Sarafidis; Charalampos Loutradis; Maria Korogiannou; Ioannis N Boletis; Smaragdi Marinaki
Journal:  Clin Kidney J       Date:  2021-07-10

Review 7.  Bioavailability, Efficacy and Safety of Generic Immunosuppressive Drugs for Kidney Transplantation: A Systematic Review and Meta-Analysis.

Authors:  Evangelos Tsipotis; Navin R Gupta; Gowri Raman; Elias Zintzaras; Bertrand L Jaber
Journal:  Am J Nephrol       Date:  2016-08-31       Impact factor: 4.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.